Secretin Activates Human Brown Fat and Induces Satiation.

• Status: Completed
• Trial end date: 2019-11-30
• Target enrollment: 0
• Participant gender: Male

Summary

15 healthy males will be studied with PET/CT, using FDG to investigate glucose metabolism, and radiowater to investigate perfusion. One scan will be performed in controlled cold exposure, to see whether subjects have cold activated brown adipose tissue. Two scans will be performed in room temperature conditions, where all subjects are blinded and randomised to receive placebo and secretin hydrochloride. PET/CT scans will be analysed blinded.

20 healthy males will also be studied with fMRI, in order to investigate brain activity responses to appetizing versus bland foods. This study will be conduced on the same patients as the PET/CT study, but additional subjects with same inclusion and exclusion criteria will be recruited. Two fMRI scans will be performed in room temperature conditions, where all subjects are blinded and randomised to receive placebo and secretin hydrochloride. fMRI scans will be analysed blinded.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Turku University Hospital
• Collaborator: Technische Universität München
• Treatments: Secretin

Criteria

Inclusion Criteria:

• healthy normal weight

Exclusion Criteria:

• cardiovascular disease, diabetes

• smoking